Caisse Des Depots ET Consignations Lowers Stock Holdings in Edwards Lifesciences Corporation $EW

Caisse Des Depots ET Consignations lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 19.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,766 shares of the medical research company’s stock after selling 12,427 shares during the quarter. Caisse Des Depots ET Consignations’ holdings in Edwards Lifesciences were worth $4,413,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EW. Vanguard Group Inc. lifted its position in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares during the period. Wellington Management Group LLP lifted its position in Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after purchasing an additional 977,933 shares during the period. Bank of New York Mellon Corp lifted its position in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Jennison Associates LLC lifted its position in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of recent analyst reports. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. UBS Group restated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research report on Friday, April 24th. Robert W. Baird upped their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $84.08 on Friday. The business’s 50 day simple moving average is $82.08 and its 200-day simple moving average is $82.41. The firm has a market capitalization of $48.47 billion, a price-to-earnings ratio of 44.72, a price-to-earnings-growth ratio of 2.10 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,747,975.32. The trade was a 2.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares in the company, valued at $1,704,682.56. This trade represents a 51.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 86,058 shares of company stock valued at $7,118,636 in the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.